As Technologies for Nucleotide Therapeutics Mature, Products Emerge
| Autor: | Fred D. Ledley, Laura M. McNamee, Jennifer M. Beierlein |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
antisense technology management oligonucleotide therapeutics Computational biology Technology assessment Biology Bioinformatics Article Novel gene 03 medical and health sciences ribozyme 0302 clinical medicine Drug Discovery Biomedical technology data analytics Product Approvals miRNA business.industry Oligonucleotide technology forecasting lcsh:RM1-950 small interfering RNA Technology management 030104 developmental biology lcsh:Therapeutics. Pharmacology 030220 oncology & carcinogenesis RNAi New product development FDA approval Molecular Medicine business Technology forecasting |
| Zdroj: | Molecular Therapy: Nucleic Acids, Vol 9, Iss C, Pp 379-386 (2017) Molecular Therapy. Nucleic Acids |
| ISSN: | 2162-2531 |
| Popis: | The long path from initial research on oligonucleotide therapies to approval of antisense products is not unfamiliar. This lag resembles those encountered with monoclonal antibodies, gene therapies, and many biological targets and is consistent with studies of innovation showing that technology maturation is a critical determinant of product success. We previously described an analytical model for the maturation of biomedical research, demonstrating that the efficiency of targeted and biological development is connected to metrics of technology growth. The present work applies this model to characterize the advance of oligonucleotide therapeutics. We show that recent oligonucleotide product approvals incorporate technologies and targets that are past the established point of technology growth, as do most of the oligonucleotide products currently in phase 3. Less mature oligonucleotide technologies, such as miRNAs and some novel gene targets, have not passed the established point and have not yielded products. This analysis shows that oligonucleotide product development has followed largely predictable patterns of innovation. While technology maturation alone does not ensure success, these data show that many oligonucleotide technologies are sufficiently mature to be considered part of the arsenal for therapeutic development. These results demonstrate the importance of technology assessment in strategic management of biomedical technologies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|